Abstract

Epidemiological and pre-clinical studies support the anti-tumor effects of ω-3 PUFAs; however, the results from human trials are mixed, making it difficult to provide dietary guidelines or recommendations of ω-3 PUFAs for disease prevention or treatment. Understanding the molecular mechanisms by which ω-3 PUFAs inhibit cancer could lead to better nutritional paradigms and human trials to clarify their health effects. The ω-3 PUFAs exert their biological activities mainly through the formation of bioactive lipid metabolites. Here we discuss the biology of cyclooxygenase, lipoxygenase and cytochrome P450 enzymes-derived ω-3-series lipid metabolites on angiogenesis, inflammation and cancer.

© 2014 Elsevier Inc. All rights reserved.

Keywords: ω-3 polyunsaturated fatty acids, cyclooxygenase, lipoxygenase and cytochrome P450

Introduction

In the U.S., there are ~1,665,540 new cases and ~585,720 deaths from cancers expected in 2014. It is estimated that 30% of cancer in developed countries are diet-related [1]. Human studies support that dietary ω-3 polyunsaturated fatty acids (PUFAs), in particular eicosapentaenoic acid (EPA, 20:5ω-3) and docosahexaenoic acid (DHA, 22:6ω-3), may reduce cancer risks [2–10]; while ω-6 PUFAs, such as linoleic acid (18:2ω-6) and arachidonic acid (ARA, 20:4ω-6), could promote tumor progression [11–16]. For example, in the ViTaminS And Lifestyle (VITAL) Cohort, current use of fish oil, but not other dietary supplements, was associated with reduced risks of breast cancer [10]. The breast cancer patients with high tissue levels of DHA also respond better to chemotherapeutic drugs [17]. In contrary to the effects of ω-3 PUFAs, studies carried out in Mexico, Sweden, Singapore and China showed that dietary intake of ω-6 PUFAs was associated with increased breast cancer risks [11,14,16,18]. This is important because current western diet contains 20–30 times more ω-6 than ω-3 PUFAs [19]. Validation of the anti-tumor effects of ω-3 PUFAs will have significant impact on public health. However, there are inconsistent results from human studies, which showed that ω-3 PUFAs had no effects...

* Corresponding author. Tel.: +1 413 545 1014.
** Corresponding author. Tel.: +1 530 752 7519.
E-mail addresses: bdhammock@ucdavis.edu (B. Hammock), guodongzhang@umass.edu (G. Zhang).

http://dx.doi.org/10.1016/j.prostaglandins.2014.07.002
1098-8823/© 2014 Elsevier Inc. All rights reserved.
or detrimental effects on cancers [22], making it difficult to provide dietary guidelines or recommendations of ω-3 PUFAs for cancer prevention or treatment.

The inconsistent results could be due to many reasons. In previous ω-3 human trials, different types, doses and treatment durations of ω-3 PUFAs were used, making it difficult to compare and analyze the results of different ω-3 studies. Besides the heterogeneity of experimental designs, the mixed results could be, in part, due to inter-individual variations to metabolize ω-3 PUFAs to generate bioactive ω-3 lipid mediators (LMs) [23–26]. The ω-3 PUFAs act in part via formation of certain LMs such as cyclooxygenase (COX)-derived prostaglandin E2 (PGE2) [27], lipoxygenase (LOX)-derived 4-hydroxy-docosahexaenoic acid (4-HDHA) [28], cytochrome P450 (CYP)-derived epoxycosapentaenoid acids (EDPs) [29], as well as unique ω-3 lipid autacoids such as resolvins and protectins [30,31]. These ω-3 LMs serve as autocrine and/or paracrine mediators to regulate inflammation and homeostasis [32]; many of these mediators are short-lived, locally produced and locally acting in response to cellular stimuli, followed with degradation or metabolism to maintain homeostasis [33]. The polymorphisms in the genes encoding ω-3 metabolism enzymes could affect the ω-3 metabolism, leading to different levels of ω-3/ω-6 LMs in tissues and varied biological responses to ω-3 supplementation. Indeed, recent research showed that there is a high degree of inter-individual variability in metabolizing ω-3 PUFAs to generate LMs upon dietary intake of ω-3 PUFAs [23]. Clearly, it is important to elucidate the specific lipid metabolizing enzymes and metabolites required for the anti-tumor effects of ω-3 PUFAs. The identified enzymes and metabolites could serve as biomarkers to screen the sub-populations which are most likely to respond to ω-3 PUFAs, or develop personalized doses for ω-3 supplementation. In addition, the bioactive ω-3 LMs could serve as biotemplates to design more potent and safer therapeutic drugs [32].

The enzymatic metabolism of ω-6 ARA leads to formation of predominately though not exclusively pro-inflammatory and pro-tumorigenic LMs, which have been shown to play a central role in tumor progression [34–36]. Compared with the ω-6-series LMs, the roles of ω-3-series LMs in angiogenesis, inflammation and cancer are less known. The ω-3 LMs were thought to be less-active mediators, while emerging evidences support that certain classes of ω-3 LMs have potent effects to modulate inflammation, angiogenesis and tumorigenesis. In this review we will discuss the biology of COX, LOX and CYP-derived ω-3 LMs on angiogenesis, inflammation and cancer. The ω-3 PUFAs also act as precursors for biosynthesis of unique lipid autacoids such as resolvins and protectins, which also regulate multiple cellular processes including inflammation, angiogenesis and cancer [31]. These ω-3 autacoids have been discussed in several recent reviews [30–32] and will not be discussed here.

2. ω-3 and ω-6 PUFAs

The ω-3 and ω-6 PUFAs are polyunsaturated fatty acids which have a double bond at the third and the sixth carbon atom from the end of the carbon chain respectively. Linoleic acid (LA, 18:2ω-6), which is an essential fatty acid and is highly abundant in common vegetable oils, is the major source of dietary ω-6 PUFA in the western diet. The average adult intake of LA in the U.S. ranges from 12 to 17 g/day for men and 9–11 g/day for women. LA can be further converted to arachidonic acid (ARA, 20:4ω-6), which is an important PUFA involved in cell signaling by generation of ω-6-series LMs (termed eicosanoids). Most research of ω-3 PUFAs have focused on EPA and DHA. Food sources of EPA and DHA include fish and fish oil supplements. Fish oil is among the most popular dietary supplements in United States. It is the most popular nonvitamin/nonmineral supplements in adults and the second most popular in children. In addition, major food companies are increasingly adding ω-3 PUFAs to various foods as value-added ingredients. FDA has approved Lovaza®, a mixture of EPA and DHA ethyl ester, as a prescription drug to treat hypertriglyceridemia (high levels of triglycerides). Another drug Vascepa® that is a pure EPA ethyl ester is currently seeking approval from FDA targeting hypertriglyceridemia. Recent technology development, using transgenic yeast, algae or supercritical carbon dioxide separation, allows the industry to prepare large-scale of highly purified EPA or DHA. Diets with a ω-6 to ω-3 PUFA ratio of 1 are recommended by nutritionists, however, current western diets have a ratio of 20–30 due to too much consumption of LA and too low consumption of ω-3 PUFAs [19]. Due to the high dietary intake of ω-6 PUFAs, ARA is among the most abundant PUFAs in most tissues. The ω-3 PUFAs are highly enriched in retina and brain tissues, mainly in the form of DHA, the tissue levels of EPA are usually low [37].

3. Molecular mechanisms of ω-3 PUFAs on cancer

Recent research shows that the lipid signaling is deregulated in tumor tissues, leading to increased production of pro-inflammatory and pro-tumorigenic eicosanoids from ARA in the tumor microenvironment. For example, the expressions of delta-6-desaturase which is a rate-limiting enzyme to convert linoleic acid to ARA, as well as phospholipases which release ARA from membrane phospholipids to initiate the biosynthesis of eicosanoids, are significantly up-regulated in tumor tissues [38,39]. The expressions of pro-tumorigenic lipid metabolizing enzymes, such as COX-2, 5-LOX and CYP epoxigenases, have been reported to be up-regulated in tumors [34,36]; while the anti-tumorigenic enzymes such as 15-LOX–1 are down-regulated [34]. Together, these changes lead to a supportive microenvironment to support tumor progression.

An important mechanism for the health-promoting effects of ω-3 PUFAs is that they suppress the metabolism of ARA to generate eicosanoids [40]. Upon dietary consumption, ω-3 PUFAs, including EPA and DHA, are incorporated into the membrane phospholipids at the expense of ω-6 ARA. Upon cellular stimulation, the incorporated ω-3 and ω-6 PUFAs are enzymatically released to generate intracellular free fatty acids (FFAs), which are rapidly metabolized by COX, LOX and CYP enzymes to generate ω-3-series and ω-6-series LMs. EPA and DHA inhibit the formation of ARA-derived ω-6-series LMs via multiple mechanisms, including reduced release of ARA from membrane phospholipids, inhibition of the enzymatic activities of the metabolizing enzymes, and direct competition with ARA for the enzymatic conversions. Besides inhibition of enzymatic metabolism of ARA, EPA and DHA also serve as alternative substrates of the lipid metabolism enzymes, leading to increased formation of ω-3-series LMs. Some of these mediators have potent effects to inhibit inflammation, angiogenesis and cancer [28,29], and will be discussed below.

4. COX-derived ω-3 LMs in angiogenesis, inflammation and cancer

The COX-2 pathway plays a critical role in angiogenesis, inflammation and cancer (Fig. 1) [34]. The COX-2 metabolite of ARA, prostaglandin E2 (PGE2), is widely known to promote inflammation, neoangiogenesis, primary tumor growth and metastasis. Increased expression of COX-2 has been observed in many tumor tissues [34]. COX-2 inhibitors, including non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2 selective inhibitors (coxibs), have been shown to reduce cancer risks [41,42]. However, the life-threatening cardiovascular risks as
well as other adverse effects induced by long-term and high-dose use of these drugs have jeopardized their therapeutic applications [43,44].

The ω-3 PUFAs reduce cancer risks via COX-2-dependent mechanisms. Human studies support that polymorphisms in the genes encoding COX-2 modulate the anti-tumor effects of ω-3 PUFAs [45,46]. EPA and DHA reduced the formation of COX-2-derived PGE2, which contributes to the beneficial effects of ω-3 PUFAs [40]. DHA is widely believed not to be a substrate of COX enzymes, although it has been reported that DHA is converted to COX-2 to form hydroxyl DHA, which is further metabolized to generate electrophilic LMs with anti-inflammatory actions [47]. EPA has been shown to be an alternative substrate of COX-2, which converts it to the ω-3-series of prostaglandin termed prostaglandin E3 (PGE3) and other LMs. Compared with ARA, EPA is a poor substrate for COX enzymes [48,49]. Previous studies have shown that PGE3 has less detrimental or even beneficial effects on cancer, the biology of PGE3 was discussed in a recent review [27]. PGE3 has been shown to have less pro-inflammatory and pro-angiogenic effects than PGE2. In NIH 3T3 fibroblasts, PGE2 induced cell proliferation while PGE3 had no effect in the same dose range. Both PGE2 and PGE3 induced COX-2 transcription in NIH 3T3 cells and IL-6 production in RAW 264.7 cells, but PGE3 had a significantly reduced pro-inflammatory effect [50]. In human endothelial cells, PGE2 further increased Ang2 expression induced by a combination of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), while PGE3 had no such effect [51]. PGE3 has also been shown to inhibit cancer cell proliferation and invasion. At a dose of 1 μM, PGE2 had no effect, while PGE3 inhibited proliferation of lung cancer A549 cells [52]. PGE3 also inhibited proliferation and induced apoptosis in B16F10 melanoma cells via mechanisms involving increased expression of PTEN [53]. In a Matrigel-based Boyden chamber assay, PGE3 inhibited cell invasion in the highly aggressive brain-metastatic melanoma 70W cell line [54]. The cellular receptors of PGE3 have not been confirmed; some studies have shown that PGE3 binds to the same receptors as PGE2 with reduced affinity and potency [27,55]. Further, a recent study showed that Δ12-prostaglandin J3 (Δ12-PGJ3), which is a novel COX-derived metabolite of EPA, potently inhibited progression of leukemias in animal models [56].

5. LOX-derived ω-3 LMs in angiogenesis, inflammation and cancer

The metabolism of PUFAs by LOX enzymes leads to the formation of leukotrienes and hydroxyl fatty acids (Fig. 2) [33]. The LOX pathway in cancer is more complicated as there are multiple isoforms of LOX enzymes. It is generally believed that 5-LOX and 12-LOX and their metabolites promote cancer, while 15-LOX-1 and 15-LOX-2 have anti-tumor effects [34,57,58]. 5-HETE, a 5-LOX metabolite of ARA, has been shown to induce angiogenesis, inflammation, and tumor progression. Pharmacological inhibitors of the 5-LOX enzyme have been shown to suppress tumor progression in animal models [34]. Since both COX-2 and 5-LOX are up-regulated in tumor tissues, dual inhibition of COX-2 and 5-LOX has been shown to cause enhanced anti-tumor effect [59,60].

The 5-LOX metabolites of ARA are generally believed to promote inflammation and angiogenesis [34]. Surprisingly, 5-LOX was recently shown to play a central role in the anti-angiogenic effect of DHA via formation of an anti-angiogenic metabolite 4-hydroxy-docosahexaenoic acid (4-HDHA) [28]. Dietary supplementation of DHA has been shown to suppress retinal angiogenesis in an oxygen-induced retinopathy model [61]. Transgenic deletion of 5-LOX greatly reduced the anti-angiogenic effect of DHA, while deletion of
COX-1/2 or 12/15-LOX had little effect, suggesting a central role of 5-LOX in the anti-angiogenic effect of DHA [28]. The 5-LOX enzyme mediates the anti-angiogenic effect of DHA via formation of 4-HDHA, which inhibited angiogenesis through a PPAR-γ-dependent mechanism [28]. Considering the importance of angiogenesis in tumor progression, it would be important to study the effect of the 4-HDHA pathway in tumor angiogenesis and associated tumor progression and metastasis (Fig. 2).

EPA and DHA are also substrates of 15-LOX, which convert them to 15-hydroxy-eicosapentaenoic acid (15-HEPE) and 15-hydroxy-docosahexaenoic acid (17-HDHA) respectively [62,63]. Both 15-HEPE and 17-HDHA have been shown to inhibit the enzymatic activity of 5-LOX (a major enzyme to generate pro-inflammatory LMs), suggesting their potential anti-inflammatory effects [62,64]. Further animal studies demonstrate the potent anti-inflammatory effects of 17-HDHA in colitis models. In a dextran sulfate sodium (DSS)- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis model, treatment with 0.1–1 μg/animal/day 17-HDHA significantly reduced the disease activity index, body weight loss, colonic damage and polymorphonuclear infiltration in both colitis models. 17-HDHA also reduced levels of pro-inflammatory cytokines such as TNF-α, IL-1β, MIP-2, and CXCL1/KC and mRNA expression of NF-κB and adhesion molecules in colon tissue [65]. In another study, 17-HDHA also suppressed DSS-induced colitis in mice. In murine macrophage RAW264.7 cells, 17-HDHA increased phagocytosis in macrophages and promoted polarization toward an anti-inflammatory M2 phenotype [66]. These studies demonstrate the potent anti-inflammatory effect of 17-HDHA, indicating a critical role of the 15-LOX enzyme in the biological activities of DHA. 17-HDHA is a precursor for the biosynthesis of resolvins, which have also been shown to have potent anti-inflammatory effects, as discussed in recent reviews [25,26].

The 15-LOX metabolites of EPA and DHA have also been shown to directly inhibit cancer cell proliferation. EPA-derived 15-HEPE inhibited the formation of PGE2 and 5-HETE, as well as cancer cell proliferation in PC-3 and LNCaP cells [67]. DHA-derived 17-HDHA inhibited the proliferation of prostate cancer cells (PC-3, LNCaP and DU145) at doses much lower than the corresponding metabolite of ARA (15-HETE) and DHA [68]. The other 15-LOX metabolites of DHA, including 17-hydroperoxy-, 10,17-dihydroxy- and 7,17-dihydroxy-DHA, also inhibited cell proliferation via mechanisms involving activation of PPAR-γ and syndecan-1 signaling in prostate cancer cells [68]. The 15-LOX-mediated metabolism is required for the effect of DHA to induce syndecan-1 signaling and apoptosis in prostate cancer cells [69]. In another study, 17-hydroperoxy-DHA inhibited cell proliferation in neuroblastoma cells with an IC50 of 3–6 μM, compared with 12–15 μM for DHA [70].

Human studies support a central role of LOX in the effects of ω-3 PUFAs. Carriers of variant 5-LOX genotypes have been shown to increase risks for inflammation and atherosclerosis compared with the carriers of common allele. Dietary intake of ω-6 PUFA increased, while intake of ω-3 PUFA decreased, the risk of atherosclerosis only in the carriers of variant alleles but not in the common alleles [71]. This study suggests that 5-LOX may be a biomarker to distinguish people who respond to the anti-atherosclerotic benefits of ω-3 PUFAs from non-responders [71]. In terms of cancer, Wang et al. showed that there is a significant interaction of the polymorphism in the genes encoding 5-LOX-activating protein (ALOX5AP) and dietary intake of ω-6 PUFA LA in terms of breast cancer risks in a population-based case–control study in San Francisco bay area [12]. Among the women with high dietary intake of LA, carrying the ALOX5AP-4900 AA genotype was associated with higher risk of breast cancer compared with other genotypes. No such correlations were observed in women consuming low levels of LA [12]. It would be interesting to test whether dietary intervention with ω-3 PUFA would inhibit breast cancer progression in this high-risk sub-population. These two human studies demonstrate a strong diet–gene interaction, supporting the critical importance of PUFA metabolism enzyme in the biological activity of ω-3 and ω-6 PUFAs.

6. CYP-derived ω-3 LMs in angiogenesis, inflammation and cancer

The CYP pathway has two branches, converting ARA to epoxyeicosatrienoic acids (EETs) by CYP epoxygenases (largely CYP2C and CYP2J) and 20-hydroxyeicosatetraenoic acid (20-HETE) by CYP ω-hydroxylase (largely CYP4A and CYP4F) (Fig. 3) [72]. EETs have been shown to have an array of beneficial actions, including anti-inflammatory, vasodilatory, anti-hypertensive, renal-protective, cardio-protective, and tissue regenerative actions. Pharmacologically inhibitors of soluble epoxide hydrolase (sEH, the major enzyme to degrade EETs) which stabilize and increase EETs, are being developed to treat many human disorders [72]. 20-HETE has been shown to have predominately detrimental effects, inducing inflammation, vasoconstriction, hypertension, and cardiovascular problems. Pharmacological inhibitors of 20-HETE biosynthesis have been shown to alleviate many disease states in animal models [73].

The roles of EETs and 20-HETE in cancer have not been well studied. EETs are mildly pro-angiogenic, stimulating endothelial
cell proliferation, migration, invasion and tube formation [72], as well as tissue regeneration [74]. Due to the pro-angiogenic actions, increased levels of EETs stimulate primary tumor growth and metastasis in implantable and spontaneous transgenic murine tumor models [75]. On the other hand, EETs are anti-inflammatory, where increased level of EETs inhibited colon cancer progression and tumor-associated inflammation in inflammation-driven colon cancer models [76,77]. 20-HETE has been shown to increase primary tumor growth in murine tumor models, in part via induction of tumor angiogenesis and inflammation. Pharmacological inhibitors targeting 20-HETE biosynthesis have been shown to inhibit tumor progression in animal models [35].

EPA and DHA have been shown to be highly efficient alternative substrates of CYP epoxygenases, leading to the formation of epoxygenated ω-3 PUFAs termed epoxyeicosatetraenoic acids (EEQs) and epoxydocosapentaenoic acids (EDPs) respectively [72,78]. CYP epoxygenases selectively catalyze the epoxidation of the terminal double bond of ω-3 PUFAs, leading to the predominant formation of 17,18-EEQ from EPA and 19,20-EDP from DHA [78–81]. Compared with other DHA epoxide regioisomers, 19,20-EDP is the poorest substrate of sEH, which increases the relative proportion of 19,20-EDP in tissues [82]. Many studies have shown that ω-3 supplementation significantly increased levels of EEQs and EDPs in animal and human plasma and tissues [78,83–87].

EEQs and EDPs have similar or more potent effects for vasodilation, anti-inflammation and analgesia than EETs [10]. EPA-derived 17,18-EEQ, as well as ARA-derived 14-15-EET, inhibited TNF-α-induced inflammation in human bronchi via NF-κB- and PPAR-γ-related mechanisms [88,89]. In a carrageenan-induced inflammatory pain model in rats, all epoxygenated PUFAs (EETs, EEQs and EDPs) inhibited inflammatory pain, while the effects of EEQs were less potent than those of EETs and EDPs [82]. Also, a 12-LOX-derived metabolite of 17,18-EEQ, 12-hydroxy-17,18-epoxyeicosatetrnaenoic acid (12-OH-17,18-EEQ), inhibited LTβ-induced neutrophil chemotaxis and polarization in vitro at a low nM range [90]. In terms of vasodilation, EDPs are

---

**Fig. 3.** Cytochrome P450 (CYP) pathway. CYP epoxygenases (largely CYP2C and CYP2J) convert PUFAs to epoxygenated fatty acids, which are chemically stable but metabolically unstable mainly due to the rapid metabolism by soluble epoxide hydrolase (sEH). CYP ω-hydroxylases (largely CYP4A and CYP4F) convert PUFAs to ω-hydroxyl fatty acids. The ω-3-series and ω-6-series epoxygenated fatty acids have similar effects on anti-inflammation or vasodilation, but have opposite effects on angiogenesis and tumor progression.
among the most potent vasodilators ever discovered (dilation $EC_{50} = 0.5–24$ pm) [91]. Direct treatment of EDPs suppressed Angiotensin II-induced hypertension in mice [92]. The CYP-mediated formation of EDPs has been hypothesized to contribute to the anti-hypertensive effects of DHA, as shown by transgenic deletion of CYP1A1 (a CYP epoxygenase enzyme) which attenuated the anti-hypertensive effects of DHA [93].

Opposite to the pro-angiogenic effects of EETs, the ω-3-series fatty acid epoxides (EEOs and EDPs) have been shown to inhibit angiogenesis. 17,18-Eeq, but not other EEOs regioisomers, inhibited cell proliferation in the immortalized endothelial cell line bEND.3 at a dose of 10 μM, while EETs at the same dose range showed opposite effects to increase cell proliferation in bEND.3 cells [94]. This study suggests a potential anti-angiogenic effect of EEOs, however, more studies are needed to characterize their effects on angiogenesis, in particular in animal models of neovascularization. Our recent study showed that EDPs potently inhibited angiogenesis, primary tumor growth and metastasis [29]. In a Matrigel plug assay in mice, all EDP regioisomers (except 4,5-EDP which is chemically unstable) inhibited VEGF-induced angiogenesis. 19,20-EDP, which is a major EDP isomer in tissues, inhibited VEGF-induced angiogenesis with an $EC_{50}$ value of 0.3 μg/animal, suggesting its potent anti-angiogenic effect. 19,20-EDP also suppressed basic fibroblast growth factor (bFGF)-induced angiogenesis in mice, suggesting a potential broad-spectrum-anti-angiogenic effect. In human endothelial cells, 19,20-EDP inhibited endothelial tube formation, migration, and production of matrix metalloproteinases, via a mechanism involving VEGF receptor 2 (VEGFR2)-dependent signaling. Given that tumor metastasis causes 90% of human cancer deaths, anti-metastatic agents are very important therapeutic agents [95]. We demonstrated that two EDP regioisomers (i.e., 16,17-EDP and 19,20-EDP, dose = 0.05 mg/kg/day), when stabilized in circulation by co-administration of a selective sEH inhibitor, suppressed ∼70% of tumor metastasis in mice [29]. In fact, EDPs are the first fatty acid metabolites to be shown to have anti-metastatic activities. Moreover, the stabilized EDP also inhibited Met-1 breast tumor growth (a highly aggressive triple-negative breast cancer model) in mice by ∼70% [29]. Our findings demonstrate potent effects of EDPs on tumor angiogenesis, however, two recent studies showed that EDPs did not impact angiogenesis in retinal angiogenesis models [96,97]. More studies are needed to characterize the effects and mechanisms of ω-3-series epoxyis and diols on angiogenesis in different disease models as it is likely that the effects of these LMs may be disease- and tissue-specific.

7. Future directions

The ω-3 PUFAs are among the most intensively studied nutritional compounds, as demonstrated by epidemiological and pre-clinical studies. However, after decades of ω-3 PSHA research, many of the health claims of ω-3 PUFAs remain controversial and have therefore had limited impact in disease prevention and treatment. The mixed results obtained with the use of ω-3 PUFAs in human trials may result in part from failing to recognize the importance of ω-3 PSHA metabolism. As we have discussed in this review, the enzymatic metabolism of ω-3 PUFAs generates ω-3-series LMs, which have potent actions to regulate inflammation, angiogenesis and tumor progression. The ω-3 LMs, rather than the parent ω-3 PUFAs (EPA or DHA), are more likely to be the ultimate bioactive species interacting with cellular targets to exert the biological effects of ω-3 PSHA supplementation. However, the vast majority of previous ω-3 PSHA research has focused on tissue levels of ω-3 PUFAs, instead of ω-3 LMs, as biomarkers to establish the nutritional or therapeutic effects of ω-3 PUFAs.

As discussed above, it is critical to elucidate the lipid metabolizing enzymes and metabolites which are required for the biological effects of ω-3 PUFAs. We expect that increased dietary intake of ω-3 PUFAs is associated with reduced cancer risks among those with genetic variant that result in increased activity of the required ω-3 metabolizing enzymes. Recently, the development of transgenic animal models, LCM/MS/MS-based lipidomics and standards for LMs has greatly facilitated the study of LMs. In the past decade, transgenic animal models with deletion or over-expression of lipid metabolism enzymes (COX-2, COX-1, 5-LOX, 12/15-LOX, CYP epoxygenase, CYP ω-hydroxylase, sEH, etc.) have been developed and many of them are commercially available. Multiple laboratories in the U.S. have developed LC-MS/MS-based lipidomics methods, which can systematically analyze >100 LMs derived from ω-3/ω-6 PUFAs using minimal plasma or tissues [98,99]. Many ω-3/ω-6 LM have been chemically synthesized and some of these LMs are commercially available, allowing cell culture and animal experiments to directly study their effects and mechanisms. These resources will greatly help to elucidate the roles of specific lipid metabolism pathway(s) and metabolite(s) in the effects of ω-3 and ω-6 PUFAs in different disease states. The knowledge obtained in pre-clinical models must be further verified in human trials. The identified lipid metabolism enzymes or metabolites could be used as biomarkers to distinguish “ω-3 responders” from “non-responders”, leading to targeted human trials. Such knowledge could also help to provide personalized dietary recommendations. For example, sub-populations carrying certain genotypes of 5-LOX or 5-LOXAP could be educated to optimize their diet [12,71]. An in-depth understanding of the molecular mechanisms of PUFAs, together with utilization of nutrigenomic and metabolicomic approaches, could lead to targeted nutritional paradigms to better understand the metabolic individuality and nutrition effects of ω-3 PUFAs on human health [100].

Acknowledgements

We acknowledge support from R01 ES027710 and NIEHS Superfund P42 ES04699 (to B.D.H.), R01 CA134659, R01 CA112356, R01 CA103828 and Research Investments in the Sciences and Engineering (RISE) Program of UC Davis (to K.W.F.), R01 CA148633 (to D.P.), and Armstrong Fund of Science Award of UMass Amherst (to G.Z.). B.D.H. is a George and Judy Marcus Senior Fellow of the American Asthma Society.

References

and phospholipase


